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ABSTRACT
Acute graft-versus-host disease (GVHD) is diagnosed by clinical and histologic criteria that are often nonspe-
cific and typically apparent only after the disease is well established. Because GvHD is mediated by donor T
cells and other immune effector cells, we sought to determine whether changes within a wide array of
peripheral blood lymphocyte populations could predict the development of GvHD. Peripheral blood samples
from 31 patients undergoing allogeneic blood and marrow transplant were analyzed for the proportion of 121
different subpopulations defined by 4-color combinations of lymphocyte phenotypic and activation markers at
progressive time points posttransplant. Samples were processed using a newly developed high content flow
cytometry technique and subjected to a spline- and functional linear discriminant analysis (FLDA)-based
temporal analysis technique. This strategy identified a consistent posttransplant increase in the proportion and
extent of fluctuation of CD3CD4CD8 cells in patients who developed GVHD compared to those that did
not. Although larger prospective clinical studies will be necessary to validate these results, this study demon-
strates that high-content flow cytometry coupled with temporal analysis is a powerful approach for developing
new diagnostic tools, and may be useful for developing a sensitive and specific predictive test for GVHD.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Acute graft-versus-host disease (aGVHD) occurs
n allogeneic hematopoietic stem cell transplant
SCT) recipients when donor-immune cells in the
raft initiate an attack on the skin, gut, liver, and other
issues of the recipient [1-6]. The pathophysiology of
VHD is currently felt to occur through several phases
2,4,6]. In the ﬁrst phase, damage by chemotherapy or
adiotherapy used in the transplant preparatory regimen
auses host tissues to secrete inﬂammatory cytokines.
his results in activation of alloreactive donor T cells
hat recognize HLA and minor histocompatability anti-
en disparities on host cells. Subsequently, the donor T
ells and other immune effectors elaborate a variety of
nﬂammatory cytokines including TNF-, IFN-, IL-
3, IL-5, and others, resulting in the widespread tissue
amage observed clinically. A variety of other immune fells, including dendritic cells, B cells, natural killer cells,
nd macrophages may also play important roles in
VHD through additional mechanisms [7-11].
It is likely that the outcome of GVHD could be
mproved if it were treated as early as possible in a
reemptive fashion, before the full-blown clinical syn-
rome develops. In addition, if the diagnosis of
VHD could be made more deﬁnitively, only those
atients who absolutely required steroids and other
mmunosuppressive medications would be treated.
urrently, however, there are no deﬁnitive methods
or detecting GVHD during its preclinical stage or to
nequivocally distinguish GVHD from infections or
rug toxicities unless there are advanced histologic
eatures on biopsy samples. For these reasons, it is
mportant to develop rapid, reliable, and accurate tests
or the prediction and diagnosis of GVHD.
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R.R. Brinkman et al.692The development of microarray technologies has
shered in a new era of diagnostic tests [12]. Attempts
ave been made to use microarrays to identify gene
xpression patterns in peripheral blood leukocytes
hat would be diagnostic of GVHD [13,14]. However,
ene microarray data provides averaged gene expres-
ion information from peripheral blood leukocyte
opulations that are actually quite heterogeneous in
ature. Consequently, the averaging effects of mi-
roarray analysis may miss important variations in
xpression of individual genes within different subsets
f cells. In addition, contributions from small popu-
ations of immune cells that may be important to the
evelopment of GVHD could be missed altogether.
Flow cytometry (FCM) offers a potential alterna-
ive to gene microarray analysis for rapidly deﬁning
omplex changes in heterogeneous populations [15-
7]. Multiple dyes, lasers, and detectors can be used to
imultaneously collect multiple ﬂuorescence emission
ignatures from cell populations representing as little
s 0.1% of the total sample [18]. Thousands of ﬂuo-
escently conjugated antibodies and ﬂuorescent dyes
re now commercially available to provide a wide
rray of cellular measurements including cell pheno-
ype, intracellular cytokine expression, cell cycle
tatus, and recently, signal transduction pathway acti-
ation. Recently, we and others have developed high-
hroughput or high-content FCM systems that can
nalyze thousands of individual samples per day to
rovide rich data sets on various types of cells [19,20].
Managing the large amounts of data generated by
igh-throughput/high content ﬂow cytometry system
s a signiﬁcant challenge. When analyzing parameters
uch as changes in immune effector cell populations
ver time that could contribute to GVHD, the tem-
oral aspect of the data introduces an additional level
f complexity as well. GVHD can occur several days
o several months after allogeneic transplant, and data
nalysis needs to account for this variation within a
tudy population. Recently, several algorithms treat-
ng time as a continuous variable have been intro-
uced to deal with this issue, including spline-based
ethods such as linear, cubic, and B-splines [21-29].
plines are mathematic representations of smooth
urves that pass through 2 or more points. Using
plines to model time series data can avoid problems
uch as data overﬁtting, and the methodology is well-
uited for the analysis of small numbers of data points
22,30].
Based on these developments, the potential now
xists for combining the advantages of high-content
ow cytometry with the power of modern bioinfor-
atics to determine if there are patterns of cells in the
eripheral blood that correlate with a variety of phys-
ologic or disease states including GVHD. Using the
igh-content FCM and the spline-based analysis
ethods outlined above in a pilot study of 31 patients 2ndergoing allogeneic transplantation, we analyzed
hether increases or decreases in the proportion of 1
r more of 121 different peripheral blood leukocyte
opulations predicted the subsequent development of
GVHD. We found that, of these populations, an
ncrease in the proportion of CD3CD4CD8
ells 7-21 days posttransplant best correlated with the
ubsequent development of aGVHD. These ﬁndings
uggest that this population should be studied further
or its possible biologic role in GVHD, and that larger
rospective clinical studies should be conducted to
alidate its predictive accuracy. In addition, this work
emonstrates that high-content FCM and spline-
ased analysis is a promising approach to developing
iagnostic tools for GVHD and other processes.
ATERIALS AND METHODS
tudy Patients
Thirty-one patients undergoing HLA matched
ibling and unrelated donor allogeneic blood and mar-
ow transplantation were enrolled at the Mofﬁtt Can-
er Center. Of the 31 patients enrolled in this study,
1 patients were diagnosed with aGVHD while 3
atients did not develop either aGVHD or cGVHD,
nd thus were used as controls. The remaining pa-
ients were not included in the analysis either because
hey (1) died prior to 100 days posttransplant and it
ould not be determined if they would have subse-
uently developed GVHD or not (n  2); (2) devel-
ped de novo chronic GVHD, which may have con-
ounded the analysis for aGVHD (n 3); (3) were lost
o follow-up (n  1); or (4) had insufﬁcient clinical
amples collected (n  1). The details of the patient
emographics, stem cell source, transplant-related
reatments, and aGVHD are summarized in Table 1.
he diagnosis and grading of GVHD was made using
reviously published criteria [31].
solation of Peripheral Blood Mononuclear Cells
Samples of peripheral blood were collected using
nstitutional review board-approved processes into
DTA containing tubes pretransplant and then weekly
or at least 100 days posttransplant. Peripheral blood
ononuclear cells (PBMCs) were isolated using Fi-
oll-Hypaque and then were cryopreserved for subse-
uent batch analysis. At the time of analysis, cells were
hawed and aliquoted into 96-well plates at 1  104 to
 105 cells per well in IMDM/10%FCS. The 96-
ell plates were then stained and analyzed as de-
cribed later.
low Cytometric High Content Screening
The 96-well plates were stained with 10 different
-color antibody combinations as described in Table
. All antibodies were obtained from BD Biosciences
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Defining a Cellular Signature of the GVHD 693San Jose, CA) except anti-CD45-PE and anti-CD8ß-
E, which were from Immunotech (Westbrook, ME).
ll staining and ﬂow cytometric analysis was done
sing a ﬂow cytometric high-content screening (FC-
CS) technique described previously [19]. Brieﬂy, in
he FC-HCS technique, all staining and analysis pro-
edures were miniaturized so that small numbers of
ells could be stained in 96-well plates with optimally
iluted ﬂuorescently conjugated antibodies. All stain-
ng procedures were performed by a Biomek
®
2000
obotic ﬂuid handler (Beckman Instruments, Schaum-
urg, IL) using a series of miniprograms developed
able 1. Summary of patient information
Patient No. Conditioning Regimen Donor Acute GVH
1 CyTBI MUD
2 CBV SIB
3 CyTBI MUD
4 CBV SIB
5 CyTBI SIB
6 BuCy SIB
7 NMT SIB
8 BuCy SIB
9 CBV SIB
10 CyTBI MUD
11 BuCy SIB
12 BuCy SIB
13 BuCy SIB
14 CyTBI MUD
15 CBV SIB
16 CyTBI MUD
17 BuCy SIB
18 CBV SIB
19 NMT SIB
20 BuCy SIB
21 CyTBI MUD
22 BuCy SIB
23 BuCy SIB
24 BuCy SIB
25 NMT SIB
26 CBV SIB
27 NMT SIB
28 CyTBI MUD
29 BuCy SIB
30 BuCy SIB
31 BuCy SIB
VHD indicates graft versus host disease.
able 2. Markers used in high content ﬂow cytometric analysis
Panel Ab-FITC (Clone) Ab-PE (Clone) A
1 CD15 (MMA) CD45 (J.33)
2 CD4 (SK3) CD8ß (2ST8.5H7)
3 CD16 (NKP15) CD2 (S5.2)
4 CD10 (HI10a) CD20 (L27)
5 TCR (WT31) TCR (11F2)
6 CD44 (L178) CD25 (2A3)
7 CD4 (SK3) CD134 (ACT35)
8 CD4 (SK3) CD122 (TU27)
9 CD45RA (L48) CD45RO (UCHL1)10 CD45RA (L48) CD45RO (UCHL1) CD3ith BioWorks™ software (Beckman Instruments,
alo Alto, CA). Cell washings were performed either
y centrifugation or by vacuum aspiration through a
lter bottom plate (Silent Screen Plate, Nunc™,
ochester NY), using a vacuum manifold (96-Filtra-
ion System, Beckman Coulter) controlled by the Bio-
orks software. Flow cytometric analysis was per-
ormed on a FACSCalibur device equipped with a
88-nm argon laser and a 635-nm red dye laser
Becton Dickinson, San Jose, CA). Samples of cells
ere delivered directly from 96-well plates to the
ACSCalibur using prototypes of a Microtiter Well
of Onset Acute GVHD Grade Clinical Outcome
III
none
IV died d 61
none died d 278
III
III
III died d 89, GVHD
none de novo cGVHD; d 122
III
I
I
III
III
II
II
II died, d 74
none
N/A died d 54
II
N/A died d 55
III
III
III
III
I died d 89
none de novo cGVHD
II
I
N/A lost to follow-up
none de novo chronic GVHD
none died d 109, disease relapse
CP (Clone) Ab-APC (Clone) Detects
(MfP9) CD33 (P67.6) Leukocytes
(SK7) CD8 (SK1) T helper/T suppressors
(SK7) CD56 (B159) NK cells
(SJ25C1) CD22 (S-HCL-1) B cells
(SK7) CD5 (L17F12) / T cells
(SK7) CD69 (L78) Activated T cells
(SK7) CD8 (SK1) Activated T cells
(SK7) CD8 (SK1) Activated T cells
(SK7) CD4 (SK3) Memory/naïve T cellsD Day
26
—
23
—
59
19
39
—
43
11
68
22
48
28
19
10
—
77
54
32
22
37
44
—
31
51
—
—b-Per
CD14
CD3
CD3
CD19
CD3
CD3
CD3
CD3
CD3(SK7) CD8 (SK1) Memory/naïve T cells
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R.R. Brinkman et al.694late device (Becton Dickinson). The BD Multiwell
late Manager/Multiwell Autosampler (MPM/MAS)
oftware (Becton Dickinson) was used for the collec-
ion and annotation of data. A typical example of the
rimary ﬂow cytometric data collected in this fashion
s depicted in Figure 1.
tatistical Analysis
The strategy for analysis of the FC-HCS data is
ummarized in Figure 2. Batch analysis of the FCS
les was performed using FlowJo Software (TreeStar,
alo Alto, CA) to determine the proportion of each
ated population within PBMCs. A total of 121 dis-
inct cell populations were deﬁned in the 10 4-color
taining panels using gates on 2-dimensional contour
lots as depicted in the representative example in
igure 1. This data was then exported as text ﬁles to
enerate tabular data. Data from samples taken be-
ween 7 and 21 days posttransplant were selected to
evelop the predictive test, because we sought to de-
elop a test that would be useful 1-2 weeks prior to the
nset of GVHD. Patient data was separated into 2
roups representing either affected (developed
GVHD) or unaffected (developed neither aGVHD
or cGVHD) patients. Splines were ﬁt to the time
eries proportion data for each cell type for each
atient. Functional linear discriminant analysis
FLDA) was then employed to generate an average
urve for each group, based on a signal plus noise
odel as previously described [32]. FLDA was per-
ormed in MATLAB (Natick, MA) based on linear
-splines with 3 vertices (ie, 1 for each week). The
igure 1. Representative FC-HCS analysis of PBMCs from patients
rom a single patient at progressive time points following transplan
eﬁning the various subpopulations are depicted in blue.eave-1-out validation (LOOCV) technique was used bo estimate the error of the FLDA classiﬁer. Last, all
he primary ﬂow cytometric data from measurements
ith high estimated sensitivity and speciﬁcity were
nspected visually to conﬁrm the spline based data
nalysis strategy.
Last, the leave-1-out validation (LOOV) tech-
ique was used to estimate the error of the FLDA
lassiﬁer.
ESULTS
To determine if a cellular signature of aGVHD
ould be deﬁned in the weeks prior to the onset of the
ull-blown clinical syndrome, PBMCs from weekly
lood samples were collected starting immediately af-
er allogeneic transplant through approximately day
100. These samples were stained using 10 panels of
-color antibody combinations (Table 2) and ﬂow
ytometry data was collected using the FC-HCS tech-
ique. Gating was performed on different populations
ithin each stained sample to generate a total of 121
opulations for subsequent statistical analysis. An ex-
mple of a representative 4-color, 6-parameter stain-
ng combination and gated subpopulations is depicted
n Figure 1. The data was then analyzed as outlined in
igure 2 for any changes in cell populations occurring
etween 7 and 21 days posttransplant that correlated
ith the development of aGVHD, which in this series
f patients occurred on average 35 days (17 days)
osttransplant.
Of the 121 populations analyzed in this fashion, a
opulation of lymphocytes that costained with anti-
VHD. Each panel depicts 2D contour diagrams of 4-color analyses
9 to day 49) using anti-CD4 and anti-CD8. Typical gates forwith G
t (day 	odies directed against CD3, CD4, and CD8
F
a
c
Defining a Cellular Signature of the GVHD 695igure 2. Summary of the data analysis pipeline. The overall strategy for performing temporal analysis of the high content ﬂow cytometry
nalysis is summarized. FC-HCS  high-content ﬂow cytometry, FLDA  functional linear discriminant analysis, LOOCV  leave-1-out
rossvalidation. The details of each of these steps is described in the Materials and Methods section.
(
h
(
d
p
d
h
C
(
f
a
p
a
o
w
t
C
s
C
c
v
a
t
t
p
C
c
(
n
C
w
s
l
c
1
t
3
r
o
s
t
F
T
w
d LDA e
R.R. Brinkman et al.696CD3CD4CD8ß cells) was found to have the
ighest correlation with the development of aGVHD
Figure 3A and B and data not shown). Patients who
id not develop aGVHD had little variation in the
roportion of CD3CD4CD8 cells in the 7-21
ays following transplant, whereas aGVHD patients
ad a higher and more variable proportion of
D3CD4CD8 cells within this time period
Figure 3A and B). To conﬁrm whether these ﬁndings
rom the spline-based analysis and FLDA reﬂected
ctual changes in the ﬂow cytometric analysis of the
atient’s peripheral blood lymphocytes rather than
n anomaly arising from the analysis strategy, the
riginal ﬂow data for the CD3CD4CD8 cells
as inspected manually for each patient at each
ime point. The gating strategy for deﬁning the
D3CD4CD8 population detected in the
pline analysis is presented in Figure 4A. The entire
D3CD4CD8 population in many patients
onsisted of 2-3 distinct subpopulations deﬁned by
igure 3. The pattern of CD3CD4CD8 cells following allog
ransplant recipients who did not develop GVHD (brown dashed li
hile patients who later developed GVHD (solid blue lines) tended
ays posttransplant. Results are shown for both raw data (A) and Farying levels of staining with antibodies directed against CD4, CD8, and CD8 (Figure 4B). Al-
hough these populations could not be clearly dis-
inguished in all patients at all time points, a sub-
opulation that coexpressed high levels of both
D8 and CD8 (CD3CD4CD8brCD8 cells)
ould typically be detected. As depicted in Figure 5
and data not shown), a visually distinct difference was
oted for the proportion of CD3CD4CD8 and
D3CD4CD8brCD8 cells between the patients
ho developed GVHD and those who did not,
upporting the temporal data analysis strategy. A
eave-1-out classiﬁer built on these observations
orrectly predicted the absence of GVHD with
00% speciﬁcity and 86% sensitivity when based on
he entire CD3CD4CD8population (Table
). Most of the predictive power of this population
esided in the CD3CD4CD8brCD8 cells as
pposed to other populations seen in this 4-color
taining panel that did not costain with 1 or more of
he antibodies to CD4, CD8, or CD8ß (Figure 4B
ansplant differentiates between patients with and without GVHD.
owed little variation in the proportion of CD3CD4CD8 cells
e signiﬁcantly higher and more variable values within the ﬁrst 7-21
stimated true signal (B).eneic tr
nes) sh
to havnd Table 3).
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Defining a Cellular Signature of the GVHD 697ISCUSSION
In the current study, we hypothesized that a sen-
itive and speciﬁc ﬂow cytometric cellular signature
or aGVHD could be developed based on analyzing a
ide array of peripheral blood cell populations for
henotypic and activation markers using high content
ow cytometry and temporal based statistical tools.
e found that the FC-HCS technique could be
eadily applied to analyzing a large clinical sample set,
nd that it efﬁciently yielded a robust data set for
ubsequent analysis. As we have reported previously,
he FC-HCS technique was able to process 500-1000
amples per day with excellent ﬂow cytometric stain-
ng and analysis proﬁles (eg, Figure 1) [19]. Although
ther high throughput ﬂow cytometry approaches are
ore efﬁcient, FC-HCS is well suited for detecting
mall populations of cells in different samples using
ultiparameter analysis because there is almost no
arryover between individual samples that could cause
alse positive results (data not shown) [20]. Because
he development of aGVHD occurred at different
ime points, it was important to use temporal analysis
ools (eg, spline- and FLDA-based methods) to look
or statistically meaningful differences in the various
eukocyte populations, between patients diagnosed
igure 4. Representative gating strategy for CD3CD4CD8 c
ith GVHD. In A, an example of the CD3CD4CD8 gatin
ononuclear cell gate deﬁned by FSC and SSC properties in the le
nally through the upper right gate in the CD4 versus CD8 conto
or various subpopulations deﬁned by the various colored gates in
emonstrates CD8 expression on CD4dimCD8br (red), CD4dim
ight-hand histogram demonstrates CD8 expression on the CD8
eft-hand contour plot.ith GVHD and the controls and to build a predictive nodel. This approach may also be suitable for other
rojects where clinical outcomes occur at variable
ime points.
In this preliminary study, the FC-HCS technique
oupled with the temporal analysis determined that
levations in the proportion of CD3CD4CD8
ells within the ﬁrst 7-21 days posttransplant pre-
icted the development of GVHD with the highest
ensitivity and speciﬁcity of any of the tested popula-
ions. A subset of these cells that also costained with an
nti-CD8 antibody (ie, CD3CD4CD8brCD8
ells) also predicted the development of GVHD with
high sensitivity and speciﬁcity, whereas other pop-
lations, which lacked coexpression of either CD4,
D8, or CD8 had relatively low predictive value
Table 3). To conclusively determine whether the
D3CD4CD8 or CD3CD4CD8brCD8
ell value is a reliable predictor of GVHD, a larger
rospective clinical study will need to be conducted
hat is sufﬁciently powered to yield statistically stron-
er results than obtained in this initial pilot study. It
ill be important in this future study to control for
eactivation of cytomegalovirus (CMV) and develop-
ent of other infectious diseases as well as additional
linical events to ensure that the ﬂow cytometric sig-
coexpression of CD4, CD8, and CD8 on these cells in a patient
gy is depicted. Cells were initially gated through a lymphocyte/
contour plot, then through a CD3 gate (middle histogram), and
. In B, the coexpression of CD4, CD8, and CD8 is demonstrated
ft-hand CD4 versus CD8 contour plot. The middle histogram
dim (blue), and CD4brCD8dim (green) subpopulations and the
(purple) and CD4CD8	 (black) subpopulations deﬁned in theells and
g strate
ft-hand
ur plot
the le
CD8
CD4	ature is speciﬁc to GVHD. In addition, other anti-
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R.R. Brinkman et al.698ody panels should be incorporated to determine if
ell populations that were not looked for in this
nitial pilot study, including T-regulatory cells and
thers, have greater sensitivity and speciﬁcity than
he CD3CD4CD8 population identiﬁed in
his study [33,34]. Ultimately, if the results pre-
ented in this initial report or more predictive pop-
lations identiﬁed in future studies are validated, a
imple weekly blood test could be constructed
here multicolor staining and ﬂow cytometric anal-
sis are performed to predict the development of
VHD. This could potentially allow for preemp-
igure 5. Representative ﬂow cytometric analysis of CD3CD4C
id not. The dot plots are from 3 representative patients 1 week pri
n d35 (the average day of GVHD development) in the 3 controive treatment of GVHD, similar to the preemptive ctrategies used for CMV reactivation following al-
ogeneic transplantation [35]. Subsequent clinical
rials could then test whether preemptive treatment
ith steroids or other immunosuppressive agents
ould improve the outcome compared to traditional
reatments that are initiated only after the clinical
yndrome is established. Other uses of this test
ould include determining how much immunosup-
ressive treatment should be initiated, when treat-
ent failure has occurred, and as a guide for taper-
ng immunosuppressive therapy. A similar approach
ay also be applicable to developing a test for
cells in patients who developed GVHD compared to patients who
e diagnosis of GVHD for the patients who developed GVHD and
did not develop GVHD.D8
or to thGVHD or other transplant related outcomes.
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Defining a Cellular Signature of the GVHD 699If the CD3CD4CD8 or CD3CD4
D8brCD8 cell populations identiﬁed in this re-
ort are validated as accurate and reliable predictors of
VHD in future studies, it will also be important to
urther clarify their biology and relevance to the clin-
cal manifestations of GVHD. This cell type appears
o be a T cell subset that coexpresses CD4, CD8
eterodimers (detected by the 2ST8.5H7 antibody,
able 2) and CD8 homodimers (detected by the
KI antibody, Table 1). One type of CD4CD8
double positive) T cell is found in the thymus as an
ntermediate stage of T cell development. These can
e found at low levels in the peripheral blood of
ealthy individuals and at higher levels during viral
nfection and other conditions where they are thought
o represent premature egress of immature thymic T
ells [35-38]. However, the CD3CD4CD8
D8 population detected in patients after allogeneic
ransplant in our study appears to express lower levels
f CD4 than typical intrathymic double-positive T
ells, and may represent a different cell type altogether
39]. This possibility is supported by reports of dou-
le-positive T cells in the lamina propria of rhesus
acaques and in mice following epicutaneous immu-
ization that have a variety of phenotypic and func-
ional properties that suggest they are mature T cells
ather than premature release of immature thymic T
ells [40,41]. Similarly, in humans, CD4dimCD8 T
ells have been observed in healthy blood donors,
IV-infected persons, and kidney transplant recipi-
nts that also appear distinct from intrathymic imma-
ure double positive T cells [42]. CD4CD8 T cells
ave been found in the blood of both HCV-infected
ersons and normal controls that have properties con-
istent with differentiated effector memory cells as
ell [35]. Together, these observations suggest that
he double-positive T cells we have observed in the
eripheral blood of persons following allogeneic trans-
lant may be mature antigen speciﬁc cells. It will be
articularly interesting in future studies to characterize
he CD3CD4CD8 CD8 population for a variety
f properties including activation and differentiation
tatus, expression of tissue and lymph node homing
able 3. Leave one out validation (LOOV) of the predictive power of C
Cell Population All Patients w/GVHD
D3CD4CD8 86/100
D3CD8CD4CD8 71/100
D3CD8dimCD8 90/0
D3CD8CD4 81/33
D3CD8CD8 81/33
D3CD4CD8 90/33
D3 90/33
VHD indicates graft versus host disease.arkers, the pattern of intracellular cytokine secre-ion, TCR V repertoire diversity, and antigen re-
ponsiveness as previously described in virally infected
ersons [35]. In addition, if a similar population were
bserved in murine models of allogeneic transplant,
ore direct studies of its relevance to GVHD could
e performed [43].
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